当前位置：药药网 / 数据中心 /奥大利亚药品评审报告(本栏目收费,不能显示细节,电话13136136841)
药品名称：
活性成份：
发布日期：-
奥大利亚药品评审报告745个记录(本栏目收费,不能显示细节,电话13136136841)
奥大利亚药品评审报告
141
Zinplava
Bezlotoxumab
2018/9/24
142
Aimovig
Erenumab
2019/9/10
143
Xeljanz
Tofacitinib (as citrate)
2019/9/10
144
Emgality
Galcanezumab
2019/9/10
145
Veltassa
Patiromer sorbitex calcium
2019/9/11
146
Xeljanz
Tofacitinib (as citrate)
2019/9/25
147
Blincyto
Blinatumomab
2019/9/30
148
Multaq / Dronedarone Winthrop / Dronedarone Sanofi
Dronedarone hydrochloride
2010/10/5
149
Sprycel
Dasatinib
2011/7/11
150
Isentress
Raltegravir
2013/6/3
151
Simponi and Simponi Smartject Injector
Golimumab (rmc)
2013/8/16
152
Daivobet 50/500
Calcipotriol / Betamethasone (as dipropionate)
2013/8/9
153
Viread
Tenofovir disoproxil fumarate
2013/10/14
154
Abraxane
Nanoparticle albumin-bound (nab) paclitaxel
2014/6/17
155
Latuda
Lurasidone hydrochloride
2014/6/20
156
Jardiance
Empagliflozin
2015/1/27
157
Humira
Adalimumab (rch)
2015/12/10
158
Esmya
Ulipristal acetate
2016/10/19
159
Gadovist 1.0
Gadobutrol
2017/1/31
160
Addaven
Nine trace elements including chromic chloride
2017/3/23